Iliofemoral Tortuosity Increases the Risk of Access-Site-Related Complications After Aortic Valve Implantation and Plug-Based Access-Site Closure

Arpad Lux, MD, PhD,a,b Lisa Müllenberg, MD,c Leo F. Veenstra, MD, Wim Dohmen, Suzanne Kats, MD, PhD,c Bart Maesen, MD, PhD,b,c and Arnoud W.J. van’t Hof, MD, PhD,a,b,c

Abstract

Background: Access-site-related complications are often related to high-risk anatomy and technical pitfalls and impair the outcomes of transfemoral aortic valve implantations (TAVIs). Calcification and tortuosity are widely recognized risk factors, and their impact on procedural planning is left to the implanting experts’ discretion. To facilitate decision-making, we introduced a quantitative measure for iliofemoral tortuosity and assessed its predictive value for access-site-related vascular and bleeding complications.

Methods: We performed a single-centre prospective cohort study of consecutive, percutaneous transfemoral TAVI performed between April 2019 and March 2020. Medical history and all-cause mortality were extracted from the electronic patient files. Arterial anatomy and calcifications were evaluated using 3mensio Structural Heart software. The primary outcome was access-site-related vascular or bleeding complications.

Results: From 580 who underwent TF TAVI and plug-based access-site closure, 108 patients met our inclusion criteria. The median age was 84 years with a 75% male distribution. On the basis of the iliofemoral tortuosity index, we divided the study population into tertiles. The primary outcome was greater in the highest tertile compared with the other two tertiles. The rate of vascular complications was 10% (n=10), 5% (n=5), and 13% (n=14), respectively (p=0.001). The rate of bleeding complications was 13% (n=13), 25% (n=25), and 15% (n=15), respectively (p=0.026).

Conclusion: Iliofemoral tortuosity increases the risk of access-site-related complications after TAVI and plug-based access-site closure. This finding emphasizes the need for an individualized approach to patient selection and procedural planning.

Keywords: Aortic valve implantation, Tortuosity, Access-site complications, Iliofemoral, Transcatheter aortic valve implantation.
Results: In this elderly, intermediate-risk population, we registered the primary outcome in 43 patients (39%), and major access-site complications in 10 patients (9.2%). Complete hemostasis was achieved in 77 patients (70.6%), by the application of the MANTA plug alone. In the group with access-site-related adverse events, compared with the group without, the tortuosity index was higher median (26% interquartile range [IQR 18%-33%] vs median 19% [IQR 13%-29%], respectively; P = 0.012), as was maximal angulation median (50° [IQR 40°-59°] vs median 43° [IQR 36°-51°], respectively; P = 0.026) were higher. Both variables had a significant effect on our primary outcome, with odds ratios (OR) of 3.1 (tortuosity, P = 0.005) and 2.6 (angulation, P = 0.020). The degree of angulation was a predictor of major complications too (odds ratio 7 [1.4-34.8]; P = 0.017).

Conclusions: Steeper angles and greater arterial elongation increase the risk of vascular and bleeding complications after femoral TAVI with the utilization of a plug-based closure device.

April 2019 and March 2020. The only inclusion criterion was that access-site closure had to be attempted with a plug-based device (MANTA vascular closure device, Teleflex Inc., Wayne, PA). Relevant medical history and all-cause mortality data were extracted from the electronic patient file. The study was approved by the ethical committee of Maastricht University and Maastricht UMC+; approval number: METC 2019-1253.

Valve implantation and access-site handling

In a dedicated hybrid operating theatre, all TF valve implantations were performed with patients under conscious sedation. At least one of the operators was highly experienced (> 3 years of experience and > 40 TF implantations per year; 4 members of the team). Echo-guided arterial puncture was left to the operator’s discretion. Patients were treated with either a balloon-expandable (Edwards Lifesciences, Irvine, CA) or a self-expandable (Medtronic plc, Minneapolis, MN) valve. Per protocol, valves were advanced via their manufacturer-dedicated sheaths (e-sheath [Edwards Lifesciences] or InLine sheath [Medtronic] / sheathless). If the usual preoperative assessment suggested significant tortuosity, then the self-expandable valves were advanced via a guiding-sheath from Cook Medical (Bloomington, IN). Per protocol, a plug-based vascular closure device was used (MANTA). Device deployment depth was based on the stop-flow measurement. Until December 2019, 2.0 cm was added to the measured depth; after December 2019, this depth was reduced to 1 cm per a change in the manufacturer instructions. Any needed venous puncture was performed on the contralateral side. Anticoagulation and any other antiplatelet therapy other than acetylsalicylic acid were discontinued before the procedure. Anticoagulation was bridged in the following specific situations: atrial fibrillation with a Congestive Heart Failure, Hypertension, Age (≥ 75 Years) (doubled), Diabetes Mellitus, Stroke (doubled), Vascular Disease, Age (65-74) Years, Sex Category (Female) (CHA2DS2-VASc score ≥ 8; mechanical heart valves (not in aortic position); and venous thromboembolism for ≤ 3 months. Bridging was carried out using low-molecular-weight heparin during the day of the procedure. Compression bandage was not routinely placed.

Assessment of vascular and bleeding complications

Arterial closure was scored with a semi-subjective classification: complete arterial hemostasis (minimal subcutaneous oozing permitted); manual compression for > 10 minutes; and pressure bandage or surgical intervention required. Vascular and bleeding complications of the TAVI access site were closely monitored and registered until the fourth postoperative day. Complications of the adjunctive arterial access sites were not included in this analysis, including daily inspection and palpation of the inguinal area and monitoring of hemoglobin levels. An ultrasound examination was done in cases of suspicion of a possible pseudoaneurysm. Pseudoaneurysms were treated according to the advice of vascular surgeons (eg, thrombin injections or surgical repair). At 6 weeks of regular follow-up, patients were asked if they had any access-site-related problems, which were then examined and/ or treated by a medical professional.

Assessment of iliofemoral anatomy

All patients who were accepted for TAVI were screened with multidetector computed tomography angiography to assess the access routes and determine appropriate valve sizes. These images were analyzed using 3mensio Structural Heart
software (version 10.0, Pie Medical Imaging BV, Maastricht, The Netherlands). Tortuosity index, angulation, and calcification index were determined for the iliofemoral tract of the access site. We adapted 2 quantification methods to adequately measure tortuosity and calcification. To acquire a tortuosity index, the true arterial length (centreline of flow) and the direct distance between the aortic bifurcation and the femoral bifurcation were measured, and their relation was determined: ([centreline of flow / direct distance] - 1) * 100). Maximal angulation was measured over the centreline with an arm length of 15 mm. (Fig. 1)

Calcification was measured between the aortic bifurcation and the femoral bifurcation, as this trajectory corresponds well to the length of sheath used for the introduction of the delivery device, and both locations are easily and reproducibly identified. Calcium volume (in mm³) was quantified using an individual Hounsfield unit (HU) threshold to compensate for the contrast-agent density. The HU of 3 noncalcified sections in the selected area was measured and averaged, and an additional 200 HU was added to this number, and a volume filter for lesions smaller than 5 mm³ was applied. To obtain the calcification index, the calcium volume was divided by the total volume of the selected area (total vessel volume) and multiplied by 100. We also performed a semiquantitative calcification scoring as previously described: 0, no calcification; 1, mild calcification; 2, moderate calcification; and 3, severe calcification. Finally, the minimal arterial lumen diameter of the iliofemoral tract was measured.

Endpoints

The primary outcome was any access-site-related vascular or bleeding complication, as defined by the most recent Valve Academic Research Consortium (VARC)-2 criteria. For each patient, the most severe periprocedural complication was scored. Secondary outcomes included the state of the access site directly after MANTA closure, post-procedural

Figure 1. Vascular assessment of the preoperative multidetector computed tomography angiography. (A) Tortuosity index: ([centreline (shown by the yellow line) of flow distance / direct distance (shown by the white line)] – 1) *100; an example of a patient with (left) a low tortuosity index and (right) a high tortuosity index. (B) Maximal angulation; measured over the centreline with an arm length of 15 mm; an example of a patient with (left) a low maximal angulation and (right) a high maximal angulation. The measured angle is demonstrated on the left side (white lines). (C) Calcification index; calcium volume and total vessel volume were measured using the Hounsfield unit; an example of a patient with (left) a non-calciﬁed iliofemoral tract and (right) a severely calcified iliofemoral tract.
hospitalization. Complications related to the non-TAVI access sites were not included in the analysis.

**Statistical analysis**

Statistical analysis was performed using SPSS version 26.0 (IBM Corp., Armonk, NY). All continuous variables are presented as mean ± standard deviation (SD), or median with interquartile range (IQR), depending on the distribution. Normality was tested with normality plots and the Shapiro-Wilk test, and group comparisons were done with the Student t test or the Mann-Whitney U test. Categorical variables are presented as frequencies with percentages, and were compared with the χ² test. The correlation of calcium index and calcium score was tested with bivariate correlation and described with the Pearson coefficient. Binary logistic regression analysis was used to identify variables associated with access-site-related vascular or bleeding complications after MANTA closure. Cutoff values for tortuosity index and angulation were selected by visual analysis of their empirical receiver operating characteristic curves (vascular and bleeding complications registered). Both variables were added as categorical variables to the univariable regression model. For the multivariable model, the tortuosity index and angulation were merged as one categorical variable with 3 categories—high TI, high angulation, or both. A P value < 0.05 was considered statistically significant.

**Results**

**Baseline characteristics**

Within the study period, 109 eligible patients consented to participate in our registry. Their baseline characteristics are summarized in Table 1. Most of these elderly patients (median age: 79 years [IQR 75–81 years]) were at intermediate surgical risk (Logistic EuroScore median 7.24 [IQR 4.61–10.84]), had hypertension (88%) and hypercholesterolemia (77%), and used at least one type of anticoagulant or antiplatelet agent (81%). The prevalence of peripheral artery disease was rather low (11%).

**Access site and valve placement**

In almost all patients (97%), a right-sided approach was used, and in 23%, femoral arterial access was obtained under ultrasound guidance. In 8.7%, more than one arterial puncture attempt was required. Interventional cardiologists performed 76% of the procedures. Balloon-expandable valves were implanted in 60% of the patients. Operators

| Table 1. Baseline characteristics |
|----------------------------------|
| Characteristic                  | All patients (n = 109) | With complication (n = 43) | Without complication (n = 66) | P   |
|---------------------------------|------------------------|---------------------------|-------------------------------|-----|
| Age, y                          | 79 [75–81]             | 79 [75–81]                | 79 [74–82]                    | 0.867|
| Female gender                   | 49 (45)                | 15 (35)                   | 34 (52)                       | 0.088|
| BMI, kg/m²                       | 27.2 [24.2–30.5]       | 27.3 [24.3–30.6]          | 27.2 [24.6–29.8]              | 0.963|
| Logistic EuroSCORE              | 7.24 (4.61–10.84)      | 6.13 [4.46–9.13]          | 7.72 [4.73–12.25]             | 0.223|
| COPD                            | 16 (15)                | 6 (14)                    | 10 (15)                       | 0.863|
| Peripheral artery disease       | 12 (11)                | 3 (7)                     | 9 (14)                        | 0.358|
| Hypercholesterolemia            | 77 (71)                | 32 (74)                   | 45 (60)                       | 0.485|
| Pulmonary hypertension          | 36 (33)                | 15 (35)                   | 21 (32)                       | 0.739|
| Hypertension                    | 96 (88)                | 37 (86)                   | 59 (89)                       | 0.598|
| History of CVA or TIA           | 19 (17)                | 8 (19)                    | 11 (17)                       | 0.794|
| Prior cardiac surgery           | 15 (14)                | 5 (12)                    | 10 (15)                       | 0.602|
| Aortic valve                    | 4 (4)                  | 1                         | 3                             |       |
| Mitral valve                    | 1 (1)                  | 1                         | 0                             |       |
| Preoperative hemoglobin, mmol/L | 8.0 ± 0.96             | 8.2 ± 0.84                | 7.9 ± 1.02                    | 0.118|
| Preoperative kidney function, ml/min per 1.73 m² | 63 [47–76]             | 68 [52–76]                | 61 [47–76]                    | 0.466|
| Severely decreased kidney function (GFR < 30) | 11 (10)               | 3 (7)                     | 8 (12)                        | 0.522|
| Aortic valve area, cm²           | 0.8 [0.7–0.9]          | 0.80 [0.66–0.90]          | 0.80 [0.70–0.96]              | 0.314|
| Mean pressure gradient, mm Hg   | 44 [36–60]             | 49 [39–63]                | 40 [34–53]                    | 0.062|
| Left ventricular ejection fraction, % | 55 [45–60]             | 55 [45–60]                | 55 [45–60]                    | 0.962|
| Type of antithrombotic therapy  |                        |                           |                               |     |
| OAC                             | 15 (14)                | 7 (16)                    | 8 (12)                        |       |
| NOAC                            | 24 (22)                | 9 (21)                    | 15 (25)                       |       |
| Antiplatelet therapy            | 47 (43)                | 18 (42)                   | 29 (44)                       |       |
| (NOAC and antiplatelet agent)   | 2 (2)                  | 1 (2)                     | 1 (2)                         |       |
| INR                             | 1.05 [1.01–1.15]       | 1.06 [1.02–1.17]          | 1.04 [1.01–1.14]              | 0.518|

Values are n (%), mean (± standard deviation), or median [interquartile range], unless otherwise specified.

- BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GFR, glomerular filtration rate; INR, international normalized ratio; NOAC, non-vitamin K oral anticoagulant; OAC, oral anticoagulant, vitamin K antagonist; TIA, transient ischemic attack.

* Aortic valve area n = 98.
1 Mean pressure gradient n = 93.
2 INR n = 100.
Tortuosity index was significantly higher in the group with access-site-related vascular or bleeding complications, compared to the group without (26% [18%-33%] vs 19% [13%-29%]), respectively; \( P = 0.012 \) as well as maximal angulation of the access site (50° [40°-59°] vs 43° [36°-51°]), respectively; \( P = 0.026 \). Calcification index, calcium score, and minimal arterial lumen diameter across the iliofemoral system on the TAVI side were comparable between groups (Table 3). The calcium index did show a good correlation with the widely used semiquantitative calcium score (Pearson correlation: 0.818, \( P < 0.001 \); Fig. 2).

**Primary and secondary clinical outcomes**

In total, 43 patients (39%) had one or more primary access-site-related vascular or bleeding complications. Ten of these patients had a major complication, 8 had a significant drop in their hemoglobin level (> 1.86 mmol/L; VARC-2 cutoff value), and 1 had a perforation at the access site. The remaining 34 patients had minor complications, hematomas or a pseudoaneurysm (Table 4).

Direct arterial hemostasis was achieved in 77 patients with no access-site-related complications. In the remaining 34 patients, primary and secondary clinical outcomes were comparable between groups. Patients with vs without TAVI access-site-related vascular and bleeding complications (major or/and minor) had comparable 30-day and 1-year mortality rates (Table 2). Patients with major vascular and bleeding complications had higher 1-year mortality than those without (3 [30%] vs 6 [61%]). In 7 cases, the cause of death is unknown; the other deaths were not access-site-related (hemorrhagic stroke or cancer).
Tortuosity and the risk of vascular complications

After visual assessment of their respective receiver operating characteristic curves, a cutoff value of 49.5 degrees was chosen for the maximal angulation (sensitivity 57%; specificity 70%), and 22.8% was chosen for the tortuosity index (sensitivity 62%; specificity 61%). Univariable binary regression analysis showed that only maximal angulation and tortuosity index could have had a significant effect on TAVI access-site related vascular and bleeding complications (major and minor), with odds ratios (ORs) of 3.4 ($P = 0.005$) and 2.8 ($P = 0.012$), respectively. The effect of other, traditional risk factors remained insignificant (Supplemental Table S1). We added the combination of these variables (high tortuosity index, high degree of angulation, or both), together with an echo-guided puncture, to an age- and gender-adjusted multivariable model. Patients with both high angulation and significant tortuosity had an increased risk for access-site-related vascular complications (OR 4.7, confidence interval [1.65-13.20]; $P = 0.004$; Supplemental Table S2). Although the event rate of major complications was relatively low, the same angulation cutoff proved to be a predictor of major complications as well ($P = 0.017$; OR 7, confidence interval [1.4-34.8]).

**Discussion**

This prospective single-centre study identified arterial tortuosity, elongation, and especially angulation of the iliofemoral arteries as important predictors of access-site-related vascular and bleeding complications in TF TAVI procedures using the MANTA closure device. Also, our results indicate that routine, semi-objective screening of preoperative computed tomography scans cannot prevent all tortuosity-related bleeding complications.

The incidence of major vascular and bleeding complications and unplanned vascular repairs has decreased within the intermediate- and lower-risk population, compared to that in the first high-risk TAVI trials. Yet, both our data and the available literature show that these events still affect short- and long-term outcomes in up to 4%-7.5% of the TAVI population. The incidence of major vascular and bleeding events in our cohort matches the aforementioned historical data, although we observed more minor complications than most other groups reporting on minor events ($\sim 3\%-30\%$). A plausible explanation for this difference could be our close and prospective monitoring of events and the slight differences in definitions.

**Table 4.** Access-site-related vascular and bleeding complications after MANTA vascular closure device (Teleflex Inc., Wayne, PA) closure

| Category                        | Frequency | Rate (%) |
|---------------------------------|-----------|----------|
| Major bleeding complications     | 8 (7.3)   |          |
| Hemoglobin drop > 1.86 mmol/L*  | 8         |          |
| - Pseudoaneurysm + access-site hematoma | 1        |          |
| - Large access-site hematoma    | 6         |          |
| - Small access-site hematoma    | 1         |          |
| Major vascular complications    | 2 (1.8)   |          |
| Perforation                     | 2         |          |
| - Surgical repair               | 2         |          |
| Minor vascular complications    | 3 (2.8)   |          |
| Pseudoaneurysm                  | 3         |          |
| - Surgical repair               | 3         |          |
| Minor bleeding complications    | 31 (28.4)|          |
| Access-site hematoma            | 31        |          |
| - Pressure bandage              | 12        |          |

Values are n, or n (%). In-hospital complications, N = 109. If one patient had more complications, only the most severe one was scored. For "hemoglobin drop," the causes are shown; for the others, the applied treatment is shown. Hemoglobin levels were only included up to and including postoperative day 4. * Cutoff value per Valve Academic Research Consortium (VARC)-2.

**Tortuosity and the risk of vascular complications**

After visual assessment of their respective receiver operating characteristic curves, a cutoff value of 49.5 degrees was chosen for the maximal angulation (sensitivity 57%; specificity 70%), and 22.8% was chosen for the tortuosity index (sensitivity 62%; specificity 61%). Univariable binary regression analysis showed that only maximal angulation and tortuosity index could have had a significant effect on TAVI access-site related vascular and bleeding complications (major and minor), with odds ratios (ORs) of 3.4 ($P = 0.005$) and 2.8 ($P = 0.012$), respectively. The effect of other, traditional risk factors remained insignificant (Supplemental Table S1). We added the combination of these variables (high tortuosity index, high degree of angulation, or both), together with an echo-guided puncture, to an age- and gender-adjusted multivariable model. Patients with both high angulation and significant tortuosity had an increased risk for access-site-related vascular complications (OR 4.7, confidence interval [1.65-13.20]; $P = 0.004$; Supplemental Table S2). Although the event rate of major complications was relatively low, the same angulation cutoff proved to be a predictor of major complications as well ($P = 0.017$; OR 7, confidence interval [1.4-34.8]).

**Discussion**

This prospective single-centre study identified arterial tortuosity, elongation, and especially angulation of the iliofemoral arteries as important predictors of access-site-related vascular and bleeding complications in TF TAVI procedures using the MANTA closure device. Also, our results indicate that routine, semi-objective screening of preoperative computed tomography scans cannot prevent all tortuosity-related bleeding complications.

The incidence of major vascular and bleeding complications and unplanned vascular repairs has decreased within the intermediate- and lower-risk population, compared to that in the first high-risk TAVI trials. Yet, both our data and the available literature show that these events still affect short- and long-term outcomes in up to 4%-7.5% of the TAVI population. The incidence of major vascular and bleeding events in our cohort matches the aforementioned historical data, although we observed more minor complications than most other groups reporting on minor events ($\sim 3\%-30\%$). A plausible explanation for this difference could be our close and prospective monitoring of events and the slight differences in definitions.
Proper preprocedural planning, taking patient- and device-related factors into account, is crucial to minimize the incidence of periprocedural bleeding and vascular complications. The interaction of anatomy and closure devices is especially interesting, as these devices have unique learning curves, usability, and applicability. To these ends, several predictors of adverse events have been proposed. 11,12 Circumferential calcification and sheath-to-femoral artery ratio are widely known predictors, and recent publications suggest that off-target puncture, unfavourable arteriotomy phenotype, small artery diameter, left femoral access, and female gender all increased the risk of vascular-closure-device-related vascular complications. 10,11 In our cohort, left femoral access use was negligible, and data on circumferential calcification were not available. We did determine a normalized iliofemoral calcification index, but this showed no relationship with the registered complications. Our preprocedural screening takes circumferential calcifications and arterial diameters, and the artery-sheath ratio, into account, and this selection bias probably diminished their effect on our study population.

Our most important and novel finding is the unfavourable influence of arterial elongation, measured by the tortuosity index and angulation, on the efficacy of a plug-based vascular closure device (MANTA). We have shown that a tortuosity index of 22.8 and an angle > 49.5 are important and synergistic predictors of VARC-2 vascular and bleeding complications. These findings connect well to the findings of Mach et al., who published similar findings (a tortuosity score of 21.2) in a population treated with suture-based closure devices and clinical experience with endovascular aneurysm repair. 13,15,16 A possible explanation could be the distortion of tortuous vessels, caused by the guidewire and temporary placement of the intravascular parts of the closure devices. This possibility may explain our findings of local bleeding complications and the need for additional manipulations to achieve complete hemostasis (30% of our patients).

We believe that objective tortuosity measurements should be incorporated into the preprocedural screening process to improve procedural outcomes. Both measurements could help with closure-device selection and in predicting access-site-related vascular and bleeding complications, although further studies are warranted to determine and validate the most relevant cutoff values.

**Strengths and limitations**

The strength of the study was its prospective design, with predefined access-site evaluation immediately after and during hospitalization. Patients were treated with one type of closure device. Access-site assessment was scored by the ward doctors. We faced a limited follow-up after hospital discharge due to pandemic measurements (COVID-19)—from March 2020 onward, patients could not be physically present in the outpatient clinic for the 6-week follow-up appointment and instead received a telephone consultation. Some of the vascular complications (eg, pseudoaneurysms) may have been missed, as no routine echocardiographic control of the access site was performed. No information is available on circumferential calcifications. Due to the small sample size, information on the influence of complications or other procedural factors on patient survival remains limited.

**Conclusion**

Steep angles and greater elongation, as measured by the tortuosity index of the iliofemoral tract, increase the risk of vascular and bleeding complications after utilization of plug-based closure devices in TAVI patients. Integrating these measurements into the TAVI workup could help improve TAVI outcomes.

**Acknowledgements**

We thank our local Business Intelligence Management team for their support and help with the data collection.

**Funding Sources**

The authors have no funding sources to declare.

**Disclosures**

The authors are all working within the same institution, and some of them are actively participating in performing transcatheter valve implantations. The authors have no conflicts of interest to disclose.

**References**

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.
2. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607.
3. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.
4. Auffret V, Lefevre T, Van Belle E, et al. Temporal trends in transcatheter aortic valve replacement in France: FRANCE 2 to FRANCE TAVI. J Am Coll Cardiol 2017;70:42-55.
5. Dencker D, Taudorf M, Luk NHV, et al. Frequency and effect of access-related vascular injury and subsequent vascular intervention after transcatheter aortic valve replacement. Am J Cardiol 2016;118:1244-50.
6. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010;55:1080-90.
7. Généreux P, Webb JG, Svensson LG, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of AoRTic TraNsEndovascular Valve) Trial. J Am Coll Cardiol 2012;60:1043-52.
8. Hayashi K, Lefèvre T, Chevalier B, et al. Transfemoral aortic valve implantation new criteria to predict vascular complications. JACC Cardiovasc Interv 2011;4:851-8.
9. Toggweiler S, Gurvitch R, Leipsic J, et al. Percutaneous aortic valve replacement: vascular outcomes with a fully percutaneous procedure. J Am Coll Cardiol 2012;59:113-8.
10. van Wiechen MP, Kroon H, Hokken TW, et al. Vascular complications with a plug-based vascular closure device after transcatheter aortic valve replacement: predictors and bail-outs. Catheter Cardiovasc Interv 2021;98:E737-45.
11. Nuis RJ, Wood D, Kroon H, et al. Frequency, impact and predictors of access complications with plug-based large-bore arteriotomy closure—a patient-level meta-analysis. Cardiovasc Revasc Med 2022;34:69-74.

12. van Wiechen MP, Tchetché D, Ooms JF, et al. Suture- or plug-based large-bore arteriotomy closure: a pilot randomized controlled trial. JACC Cardiovasc Interv 2021;14:149-57.

13. Mach M, Poschner T, Hasan W, et al. The iliofemoral tortuosity score predicts access and bleeding complications during transfemoral transcatheter aortic valve replacement: data from the Vienna Cardio Thoracic aOrtic valve registY (VICTORY). Eur J Clin Invest 2021;51:e13491.

14. Essential Medical, Inc. MANTA instructions for use 2019. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf18/P180025C.pdf. Accessed June 14, 2022.

15. Kristmundsson T, Sonesson B, Resch T. A novel method to estimate iliac tortuosity in evaluating EVAR access. J Endovasc Ther 2012;19:157-64.

16. Kyriakou F, Dempster W, Nash D. A methodology to quantify the geometrical complexity of the abdominal aortic aneurysm. Sci Rep 2019;9:17379.

17. Kim WK, Renker M, Rolf A, et al. Accuracy of device landing zone calcium volume measurement with contrast-enhanced multidetector computed tomography. Int J Cardiol 2018;263:171-6.

18. Chaikof EL, Fillinger MF, Matsumura JS, et al. Identifying and grading factors that modify the outcome of endovascular aortic aneurysm repair. J Vasc Surg 2002;35:1061-6.

19. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012;33:2403-18.

20. Beurtheret S, Karam N, Resseguier N, et al. Femoral versus nonfemoral peripheral access for transcatheter aortic valve replacement. J Am Coll Cardiol 2019;74:2728-39.

21. Fonseca P, Almeida J, Bettencourt N, et al. Incidence and predictors of vascular access site complications following transfemoral transcatheter aortic valve implantation. Rev Port Cardiol 2017;36:747-53.

22. Reinthaler M, Aggarwal SK, De Palma R, et al. Predictors of clinical outcome in transfemoral TAVI: circumferential iliofemoral calcifications and manufacturer-derived recommendations. Anatol J Cardiol 2015;15:297-305.

Supplementary Material
To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at https://doi.org/10.1016/j.cjco.2022.03.006.